Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6662526 | 0.85 | LMNA (0.42) | ALDH1A1LMNAGAAL3MBTL1POLB | |
| SCHEMBL8423965 | 0.81 | ALDH1A1 (0.40) | ALDH1A1LMNAGAAL3MBTL1POLB | |
| SCHEMBL9060638 | 0.80 | ALDH1A1 (0.39) | ALDH1A1PKMTDP1LMNAGAA | |
| SCHEMBL9060642 | 0.80 | ALDH1A1 (0.39) | ALDH1A1PKMTDP1LMNAGAA | |
| Fumaric Acid SCHEMBL4968361 | 0.76 | POLB (0.40) | ALDH1A1PKMTDP1GAAL3MBTL1 | |
| Fumaric Acid SCHEMBL2908209 | 0.76 | POLB (0.40) | ALDH1A1PKMTDP1GAAL3MBTL1 | |
| Fumaric Acid SCHEMBL2908206 | 0.76 | POLB (0.40) | ALDH1A1PKMTDP1GAAL3MBTL1 | |
| SCHEMBL2707104 | 0.75 | SIGMAR1 (0.40) | ALDH1A1PKMTDP1LMNAGAA | |
| SCHEMBL6553147 | 0.75 | SIGMAR1 (0.40) | ALDH1A1PKMTDP1LMNAGAA | |
| SCHEMBL9060399 | 0.74 | ALOX15 (0.41) | ALDH1A1PKMTDP1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077730-A1 | Carbocyclic halo amines such as N,N-dimethyl-1-(1-(4-chloro-phenyl)cyclobutyl)-3-methylbutyl amine hydrochloride, used for reducing insulin resistance in humans having diabetes | BAILEY CLIFFORD JAMES (GB) | 2004-04-22 | — | — | US | claimed |
| EP-0946181-B1 | USE OF 2-(2-MORPHOLINOPHENYL) GUANIDINE DERIVATIVES FOR THE TREATMENT OF DIABETES COMPLICATIONS | KNOLL GMBH (DE) | 2004-02-25 | — | — | EP | claimed |
| US-6617360-B1 | Arylcyclobutylalkylamines, especially sibutramine; and a an oral insulin secretagogue such as 1,1-dimethyl-2-(2-morpholinophenyl)guanidine fumarate or a sulfonyl urea, or an insulin sensitizer | KNOLL AKTIENGESELLSCHAFT (DE) | 2003-09-09 | — | — | US | claimed |
| US-6133267-A | Use of 2-(2-morpholinophenyl) guanidine derivatives for the treatment of diabetes complications | KNOLL AKTIENGESELLSCHAFT (DE) | 2000-10-17 | — | — | US | claimed |
| US-11331379-B2 | Compositions and methods for regulating pancreatic beta cell function using adipsin | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20200093900-A1 | COMPOSITIONS AND METHODS FOR REGULATING PANCREATIC BETA CELL FUNCTION USING ADIPSIN | DANA-FARBER CANCER INSTITUTE, INC. | 2020-03-26 | — | — | US | disclosed |
| US-10328131-B2 | Compositions and methods for regulating pancreatic beta cell function using adipsin | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20170072028-A1 | COMPOSITIONS AND METHODS FOR REGULATING PANCREATIC BETA CELL FUNCTION USING ADIPSIN | DANA-FARBER CANCER INSTITUTE, INC. | 2017-03-16 | — | — | US | disclosed |
| EP-1509545-B1 | HOMOTRIMERIC EXTENDED OBG3 GLOBULAR HEAD AND USES THEREOF | SERONO GENETICS INST SA (FR) | 2010-08-25 | — | — | EP | disclosed |
| US-7671024-B2 | OBG3 globular head and uses thereof | SERONO GENETICS INSTITUTE S.A. (FR) | 2010-03-02 | — | — | US | disclosed |
| US-20090099076-A1 | OBG3 Globular Head and Uses Thereof | SERONO GENETICS INSTITUTE S.A. (FR) | 2009-04-16 | — | — | US | disclosed |
| US-7459433-B2 | Homotrimeric extended OBG3 globular head and uses thereof | SERONO GENETICS INSTITUTE, S.A. (FR) | 2008-12-02 | — | — | US | disclosed |
| US-20020091080-A1 | OBG3 globular head and uses thereof for decreasing body mass | SERONO GENETICS INSTITUTE S.A. (FR) | 2002-07-11 | — | — | US | disclosed |
| US-20020037849-A1 | OBG3 globular head and uses thereof for decreasing body mass | SERONO GENETICS INSTITUTE S.A. (FR) | 2002-03-28 | — | — | US | disclosed |
| US-6174925-B1 | REDUCING INSULIN RESISTANCE IN HUMANS IN WHOM IMPAIRED GLUCOSE TOLERANCE OR NON-INSULIN DEPENDENT DIABETES MELLITUS HAVE NOT PRESENTED BUT IN WHOM THERE IS INCREASED RISK OF DEVELOPING SUCH CONDITIONS BY ADMINISTERING SIBUTRAMINE ANALOGUE | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-01-16 | — | — | US | disclosed |
| US-6133267-A | Use of 2-(2-morpholinophenyl) guanidine derivatives for the treatment of diabetes complications | KNOLL AKTIENGESELLSCHAFT (DE) | 2000-10-17 | — | — | US | disclosed |
| EP-0946181-A1 | USE OF 2-(2-MORPHOLINOPHENYL) GUANIDINE DERIVATIVES FOR THE TREATMENT OF DIABETES COMPLICATIONS | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-10-06 | — | — | EP | disclosed |
| EP-0927028-A1 | USE OF SIBUTRAMINE ANALOGUES TO PREVENT THE DEVELOPMENT OF DIABETES | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998026782-A1 | USE OF 2-(2-MORPHOLINOPHENYL) GUANIDINE DERIVATIVES FOR THE TREATMENT OF DIABETES COMPLICATIONS | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998011884-A1 | USE OF SIBUTRAMINE ANALOGUES TO PREVENT THE DEVELOPMENT OF DIABETES | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077730-A1 | Carbocyclic halo amines such as N,N-dimethyl-1-(1-(4-chloro-phenyl)cyclobutyl)-3-methylbutyl amine hydrochloride, used for reducing insulin resistance in humans having diabetes | GPR119, CLIC1, SLC5A1 | ALDH1A1 1639/4885PKM 2295/4885TDP1 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.